Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2024 to Q4 2025

Type / Class
Equity / Common Stock, no par value
Symbol
TELO on Nasdaq
Shares outstanding
32,270,909
Price per share
$1.33
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
2,332,205
Total reported value
$3,240,559
% of total 13F portfolios
0%
Share change
-474,330
Value change
-$616,945
Number of holders
31
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
DEJORIA JOHN PAUL 5.5% $2,626,852 1,774,900 John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity 09 Sep 2025

As of 30 Sep 2025, 31 institutional investors reported holding 2,332,205 shares of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO). This represents 7.2% of the company’s total 32,270,909 outstanding shares.

Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,249,077 $1,661,275 +$55,553 $1.33 12
2025 Q3 2,332,205 $3,240,559 -$616,945 $1.39 31
2025 Q2 2,807,449 $3,509,640 -$1,509,830 $1.25 42
2025 Q1 3,692,775 $11,927,828 +$377,556 $3.23 42
2024 Q4 3,556,770 $14,654,749 +$6,085,188 $4.12 36
2024 Q3 2,045,931 $13,136,327 +$9,006,598 $6.42 33
2024 Q2 361,326 $1,738,327 +$1,329,096 $4.81 24
2024 Q1 79,917 $413,466 +$413,466 $5.15 7